The computed 12-month bankruptcy probability of NORMAPHAR is 9.5% (elevated). For NORMAPHAR, at least two filing cycles of the annual accounts are missing. The 2023 annual accounts show negative equity (-€61,995) and a net result of -€101,665. The figures fluctuate too strongly year-on-year for a reliable trend projection. The company has been active since 2011 and the Belgian Official Gazette contains no insolvency or warning signals.
The company's story in a few sentences, from the company register, the Belgian Official Gazette and the filed annual accounts. Each number opens the document the sentence rests on.
On 2 February 2011, NORMAPHAR was incorporated.1Total assets went from €1.9m in 2018 to €26,031 in 2023 and headcount from 9.7 full-time equivalents in 2018 to 0.3 in 2022.2
Financial milestoneNBB filingFinancial milestones sit on the financial year-end date, not the filing date.Of the 13 annual accounts filed, the latest 10 are here; all 13 are under Financials.
0 of 9 deeds read
About the unread acts
We know of 9 Belgian Official Gazette acts for this company. None of them has been read yet: what they contain is neither established nor disproved here.